Scholarlink

Background <p>Various kinds of clinical characteristics predispose patients receiving voriconazole therapy to high variability of serum voriconazole level. However, little is known about the predictors of drug level variability among critically ill patients.</p> Methods <p>This retrospective study was executed to investigate the associated factors. Between January 2020 and June 2021, all adult patients with invasive pulmonary aspergillosis receiving parenteral voriconazole for more than four days during their stay in intensive care were recruited. The enrolled subjects were classified into within- and beyond-therapeutic group based on their serum voriconazole trough levels.</p> Results <p>A total of 34 patients were studied; serum voriconazole levels ranged from &lt; 0.1 to 11.38&#xa0;mg/L, and 35.3% were categorized as beyond-therapeutic group. The all-cause in-hospital mortality rate was 17.7%. Multivariate logistic regression showed that lower body mass index (BMI) value [odds ratio (OR), 15.16; 95% CI, 2.10–109.51; <i>p</i> = 0.007] and increase in total bilirubin level (OR, 9.23; 95% CI, 1.16–73.21; <i>p</i> = 0.035) were independently associated with variability of serum voriconazole troughs.</p> Conclusions <p>Further investigation of appropriate prescribing doses of voriconazole, likely with regards to BMI value, might be needed to attain target drug concentrations to achieve better clinical effectiveness and avoid drug-related toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Factors associated with beyond-therapeutic serum voriconazole trough level among critically ill patients with invasive fungal infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月22日

查看全文
  • Yi-Chien Lee,
  • Wei-Chi Ku,
  • Yi-Li Hung,
  • Yong-Chen Chen,
  • Chi-Feng Hung,
  • Jann-Tay Wang,
  • Wei-Lun Liu

摘要

Background

Various kinds of clinical characteristics predispose patients receiving voriconazole therapy to high variability of serum voriconazole level. However, little is known about the predictors of drug level variability among critically ill patients.

Methods

This retrospective study was executed to investigate the associated factors. Between January 2020 and June 2021, all adult patients with invasive pulmonary aspergillosis receiving parenteral voriconazole for more than four days during their stay in intensive care were recruited. The enrolled subjects were classified into within- and beyond-therapeutic group based on their serum voriconazole trough levels.

Results

A total of 34 patients were studied; serum voriconazole levels ranged from < 0.1 to 11.38 mg/L, and 35.3% were categorized as beyond-therapeutic group. The all-cause in-hospital mortality rate was 17.7%. Multivariate logistic regression showed that lower body mass index (BMI) value [odds ratio (OR), 15.16; 95% CI, 2.10–109.51; p = 0.007] and increase in total bilirubin level (OR, 9.23; 95% CI, 1.16–73.21; p = 0.035) were independently associated with variability of serum voriconazole troughs.

Conclusions

Further investigation of appropriate prescribing doses of voriconazole, likely with regards to BMI value, might be needed to attain target drug concentrations to achieve better clinical effectiveness and avoid drug-related toxicity.